|





 |
You will find in this section hot News articles which we feel are of
national importance to all folks. Beat
the
Press
is brought to you as a free service from AAJTS.
Be the best you can be and beat the press by reading
The
InfoJustice
Journal.
-
June 25, 2008
Risedronate (Actonel®) prevents bone loss in
IBD patients on steroids
Summary This randomized controlled trial found that
risedronate (Actonel®) prevents steroid-induced bone loss in IBD.
Basis for Study/Article The authors of this study
from England examined the efficacy of risedronate for preventing
steroid-related bone loss in patients with IBD.
Detailed Summary of Study Patients receiving
prednisolone for an IBD flare-up were randomized to receive placebo
or risedronate, in addition to calcium and vitamin D. DEXA scans of
the lumbar spine and hips were done at baseline and 8 weeks later in
73 patients (42 with ulcerative colitis, 31 with Crohn’s disease;
average age 43.5 years; 42 patients were men).
Results/Body In the lumbar spine, the patients
taking risedronate had a 1% gain in BMD vs. no change in the placebo
group after 2 months of treatment. In the total hip, neither group
experienced BMD change. In Ward’s triangle (neck of the femur), the
risedronate group had a 1% loss and the placebo group had a 2% loss.
Sources & Other Links Kriel MH, et al. Risedronate
protects against bone loss when a relapse of IBD is treated with
steroids. Abstract #T1122 presented at Digestive Diseases Week, May
2008.
Article Link (DOWNLOAD)
- June 25, 2008
IM
dexamethasone + antibiotics useful for acute exudative pharyngitis
Summary This randomized controlled trial found that for
acute exudative pharyngitis, adding a single dose of IM
dexamethasone to the antibiotic regimen relieves symptoms better
than antibiotics alone.
Basis for Study/Article The authors of this
single-center trial from Turkey tested the efficacy of a single dose
of IM dexamethasone in the treatment of acute exudative pharyngitis.
Detailed Summary of Study Adults with acute
exudative pharyngitis, sore throat, and/or odynophagia were
randomized to receive either an 8-mg IM dose of dexamethasone (n =
31) or placebo (n = 42), in addition to 3 days of azithromycin and
paracetamol (acetaminophen). Time to onset of pain relief and time
to complete pain relief were compared.
Results/Body Onset of pain relief occurred in 8.06
hours in the dexamethasone group vs. 19.90 hours in the placebo
group. Corresponding figures for complete pain relief were 28.97
hours and 53.74 hours.
Sources & Other Links Tasar A, et al. Clinical
efficacy of dexamethasone for acute exudative pharyngitis.
J Emerg Med. 2008 May 10. [Epub
ahead of print]
Article Link (NCBI)
- June 25, 2008
Tight diabetes control lowers incidence of nephropathy, vascular
eventsSummary This large study with 5
years of follow-up found that tight diabetes control (using
gliclazide [Diamicron®] and other drugs to obtain an HbA1c of 6.5%
or less) lowers the incidence of macrovascular and microvascular
events together, in particular reducing the relative risk of
nephropathy by 21%.
Basis for Study/Article The ADVANCE Collaborative
Group tested the effects of intensive glucose control on
macrovascular and microvascular outcomes in patients with type 2
diabetes.
Detailed Summary of Study 11,140 patients with type
2 diabetes were randomized to receive either standard glucose
control or intensive control (using modified-release gliclazide [Diamicron®]
and other drugs to obtain an HbA1c of 6.5% or less). After a median
follow-up of 5 years, the number of major macrovascular events (CV
death, nonfatal MI, nonfatal stroke) and major microvascular events
(nephropathy, retinopathy) was assessed.
Results/Body At follow-up, mean HbA1c levels were
6.5% in the intensive group vs. 7.3% in the standard group. Combined
major and minor macrovascular events occurred in 18.1% of the
intensive group vs. 20% of the standard group (p = 0.01). Major
microvascular events occurred in 9.4% of the intensive group vs.
10.9% of the standard group (p = 0.01). Nephropathy occurred in 4.1%
of the intensive group vs. 5.2% of the standard group. There were no
differences between the groups in the incidence of major
macrovascular events alone, retinopathy, CV death or all-cause
mortality. Severe hypoglycemia occurred in 2.7% of the intensive
group vs. 1.5% of the standard group (p <0.001).
Sources & Other Links ADVANCE Collaborative Group.
Intensive blood glucose control and vascular outcomes in patients
with type 2 diabetes. N Engl J Med.
2008 Jun 12;358(24):2560-2572.
Article Link (NCBI)
- June 25, 2008
Sequential therapy is better than standard triple therapy for H.
pyloriSummary This meta-analysis
found that 10-day sequential therapy is better than standard triple
therapy for the treatment of H. pylori
infection in treatment-naïve patients. However, the authors caution
that most of the patients in the studies they reviewed were from
Italy, only one study was double-blinded, and publication bias may
have played a role.
Basis for Study/Article Because standard triple
therapy for H. pylori infection
is unsuccessful in about a quarter of patients, the authors
conducted a meta-analysis on the efficacy of sequential therapy in
treatment-naïve patients.
Detailed Summary of Study The reviewers analyzed
data from 10 randomized controlled trials (n = 2,747) comparing
sequential vs. standard therapy.
Results/Body H. pylori
eradication rates were 93.4% in the 1,363 patients receiving
sequential therapy and 76.9% in the 1,384 patients receiving
standard triple therapy. The success rate was affected by the
patient’s smoking status, diagnosis and method of diagnosis,
resistance to clarithromycin or imidazoles, and duration of triple
therapy. Adherence rates were 97.4% for sequential therapy and 96.8%
for standard therapy. Adverse effects were similar. The authors
believe that if trials in other countries confirm the findings,
“10-day sequential therapy could become a standard treatment for
H. pylori infection in
treatment-naïve patients.”
Commentary What is sequential therapy? Triple
therapy has been common for some time. One article detailing one
sequential regimen is available at:
http://www.annals.org/cgi/content/abstract/146/8/556
Briefly; the protocol used was:
| • |
|
Days 1-5
| › |
|
40 mg pantoprazole BID |
| › |
|
1 gram amoxicillin BID |
|
| • |
|
Days 6-10
| › |
|
40 mg pantoprazole BID |
| › |
|
500 mg clarithromycin BID |
| › |
|
500 mg tinidazole BID |
|
Grant E. Fraser, M.D.
MedAlert Editor
Sources & Other Links Jafri NS, et al.
Meta-analysis: Sequential therapy appears superior to standard
therapy for Helicobacter pylori
infection in patients naive to treatment.
Ann Intern Med. 2008 May 19. [Epub ahead of print]
Article Link (NCBI)
- June 18, 2008
Depression and too much or too little activity can lead to
persistent adolescent fatigueSummary Teenagers
with depressive symptoms and either sedentary or highly active lives
are at risk for persistent fatigue.
Basis for Study/Article The authors of this British study
identified risk factors for persistent adolescent fatigue, defined
as extreme tiredness twice weekly or more often in the previous
month.
Detailed Summary of Study 1,880 subjects age 11 to 16 (49%
boys, 81% nonwhite) at 28 London schools completed questionnaires in
2001 and 2003 asking about persistent fatigue, activity level,
depressive symptoms, BMI and smoking status.
Results/Body 4% (84 students) of the students
reported persistent fatigue; however, in both surveys (2001 and
2003) only 3 students reported chronic fatigue syndrome. Persistent
fatigue was more common in teens who had depressive symptoms (odds
ratio 2.0), who were sedentary more than 4 hours a day (odds ratio
1.6) or who were extremely active (odds ratio 1.5). BMI and smoking
were not factors. Severe fatigue occurred in 11% of students aged 11
to 14 years and 17% of those aged 13 to 16 years.
Sources & Other Links Viner RM, et al. Longitudinal
risk factors for persistent fatigue in adolescents.
Arch Pediatr Adolesc Med. 2008
May;162(5):469-75.
Article Link (NCBI)
-
TABLE FOR CHRONIC ANTIHYPERTENSIVE DRUGS FROM THE USFDA - 2008
| Pharmacologic Class
|
Approved Drugs |
| aldosterone antagonists
Works on the blood side of the
nephron-binds to aldosterone. |
eplerenone, spironolactone |
| alpha adrenergic blockers |
doxazosin,
phenoxybenzamine, phentolamine, prazosin,
terazosin |
| angiotensin converting enzyme
inhibitors |
benazepril, captopril,
enalapril, fosinopril, lisinopril,
moexipril, perindopril, quinapril, ramipril,
trandolapril |
| angiotensin II receptor
blockers |
candesartan,
eprosartan, irbesartan, losartan,
olmesartan, telmisartan, valsartan |
| arteriolar vasodilators |
hydralazine, minoxidil |
| autonomic ganglionic
vasodilators |
mecamylamine |
| beta adrenergic blockers |
acebutolol,
atenolol, betaxolol, bisoprolol,
carvedilol, carteolol, esmolol, labetolol,
metoprolol, nadolol, penbuterol,
pindolol,
propranolol, timolol |
| catecholamine-depleting
sympatholytics |
deserpidine, reserpine |
| central alpha-2 adrenergic
agonists |
clonidine,
guanabenz, guanfacine, methyldopa |
| calcium channel blockers |
diltiazem,
verapamil |
| dihydropyridine calcium channel
blockers |
amlodipine,
felodipine, isradipine,
nicardipine, nifedipine,
nisoldipine |
| loop diuretics |
bumetanide, ethacrynic acid,
furosemide, torsemide |
| potassium-sparing diuretics |
amiloride,
triamterene |
| renin inhibitors |
aliskiren |
| thiazide diuretics
↓
Left
ventricular hypertropy. |
chlorothiazide, hydrochlorothiazide, hydroflumethiazide,
methyclothiazide, polythiazide |
| thiazide-like diuretics |
chlorthalidone,
indapamide, metolazone |
-
BLACK BOX
WARNING FROM FDA
June 16, 2008
Audience:
Neuropsychiatric, Geriatrics
and Family medicine healthcare professionals
FDA notified healthcare professionals that both conventional and
atypical antipsychotics are associated with an increased risk of
mortality in elderly patients treated for dementia-related
psychosis. In April 2005, FDA notified healthcare professionals that
patients with dementia-related psychosis treated with atypical
antipsychotic drugs are at an increased risk of death. Since issuing
that notification, FDA has reviewed additional information that
indicates the risk is also associated with conventional
antipsychotics. Antipsychotics are not indicated for the treatment
of dementia-related psychosis. The prescribing information for all
antipsychotic drugs will now include the same information about this
risk in a BOXED WARNING and the WARNINGS section.
- FALLS AND FALL-RELATED INJURIES AMONG PERSONS
AGED 65 YEARS OLD OR GREATER
-
DRUG RECALLS
LISTED BY AUDIENCE
OF IMPORTANCE:
June 11, 2008
Having 1/2 to 1 alcoholic drink per day protects against hip
fracture
Summary
This meta-analysis found that people who have 1/2 to 1 alcoholic
drink per day have a lower risk of hip fracture compared to
nondrinkers and heavier drinkers.
Basis for
Study/Article
The authors performed a literature review to assess the effects of
moderate alcohol consumption on bone density and the risk of
osteoporotic hip fracture.
Detailed
Summary of Study
Effect sizes were pooled for hip fracture and bone density, and
results were synthesized for four outcomes: non-hip fracture, bone
density loss over time, bone response to estrogen replacement, and
bone remodeling.
Results/Body
People who had 1/2 to 1 alcoholic drink per day had a lower risk of
hip fracture compared to nondrinkers (relative risk 0.80); the
relative risk was 1.39 for those who had more than 2 drinks a day.
“A linear relationship existed between femoral neck bone density and
alcohol consumption,” but “a precise range of beneficial alcohol
consumption cannot be determined.”
Sources &
Other Links
Berg KM, et al. Association between alcohol consumption and both
osteoporotic fracture and bone density.
Am J Med. 2008
May;121(5):406-18.
Article Link (NCBI)
June 11, 2008
Obstructive sleep apnea is common in women with nocturia
Summary
Obstructive sleep apnea is common in women with nocturia, and 88% of
women with dilute nighttime urine have OSA. “We should consider a
diagnosis of OSA in all patients with nocturia,” even those with
daytime overactive bladder symptoms.
Basis for
Study/Article
The authors explored the association between obstructive sleep apnea
and nocturia in women and tested urine samples to see whether urine
concentration was predictive for sleep apnea.
Detailed
Summary of Study
21 women with nocturia (16 of them also had daytime overactive
bladder) and 10 control subjects completed nocturia questionnaires,
underwent a home sleep study and provided evening and morning urine
samples.
Results/Body
17 of the 21 women with nocturia (81%) were found to have sleep
apnea (13 of the 16 with daytime overactive bladder and 4 of the 5
without) vs. 4 of the control group. “The presence of diluted
nighttime urine in a patient with nocturia was 88% sensitive for the
presence of OSA.”
Sources &
Other Links
Lowenstein L, et al. The relationship between obstructive sleep
apnea, nocturia, and daytime overactive bladder syndrome in women.
Am J Obstet Gynecol. 2008
May;198(5):598.e1-5.
June 10, 2008
Audience:
Healthcare professionals, consumers
ETHEX
Corporation notified healthcare professionals of a voluntary recall
of a single lot of morphine sulfate 60 mg extended release tablets
(Lot No. 91762) due to a report of a tablet with twice the
appropriate thickness. Oversized tablets may contain as much as two
times the labeled level of active morphine sulfate. The lot was
distributed by ETHEX Corporation under an "ETHEX" label between
April 16th and April 27th of 2008. Opioids such as morphine have
life-threatening consequences if overdosed. Consequences can include
respiratory depression (difficulty or lack of breathing), and low
blood pressure. Many patients for whom this product is prescribed
are likely to be highly debilitated with reduced strength or energy
as a result of illness, and may be less likely to determine that a
tablet is overweight or oversized than an unimpaired individual. If
consumers have any questions about the recall, they should call
their physician, pharmacist, or other health care provider.
June 4, 2008
Adverse events associated with PCA and insulin pumps in adolescents
Summary
Over a 10-year period, there were 1,594 reports to the FDA of
adverse events associated with adolescents’ use of insulin pumps
(including 13 deaths) and 53 reports of adverse events associated
with patient-controlled analgesia pumps. “Studies need to further
identify safety problems in this age group.”
Basis for
Study/Article
After receiving five reports of deaths in adolescents associated
with insulin pumps in 2005, the FDA conducted an assessment of the
safety of insulin and PCA pumps in this population.
Detailed
Summary of Study
The authors reviewed reports submitted to the FDA from 1996 through
2005 about adverse events associated with use of insulin or PCA
pumps by adolescents (ages 12 to 21). Demographics, type of adverse
event, outcomes and contributing factors were analyzed.
Results/Body
Over a 10-year period, there were 1,594 reports of adverse events
associated with insulin pumps, including 13 deaths, 2 possible
suicide attempts, and several reports of apparently device-related
hyperglycemia or hypoglycemia. Some of the contributing factors were
compliance problems, lack of education, “sports-related activities”
and “dropping or damaging the pump.” In 82% of the events the
patient was hospitalized. There were 53 reports of adverse events
associated with PCA pumps. In half the patients received too much
medication; “tampering and noncompliance were evident in some
cases.”
The authors
suggest more studies on the safety of these devices in adolescents.
Sources &
Other Links
Cope J, et al. Adolescent use of insulin and patient-controlled
analgesia pump technology: a 10-year Food and Drug Administration
retrospective study of adverse events.
Pediatrics. 2008 May;121(5):e1133-8.
Article Link (NCBI)
-
DRUG RECALLS
LISTED BY AUDIENCE
OF IMPORTANCE:
June 02, 2008
Audience:
Consumers, pediatricians, other healthcare professionals
Abbott
notified consumers and healthcare professionals of the recall of
two lots of Calcilo XD Low-Calcium/vitamin D-Free Infant Formula
with Iron powder, a low-calcium and Vitamin D-free infant
formula specifically designed for the nutrition support of
infants and children with hypercalcemia. The product,
distributed in the United States between 06/06/06 and 04/17/08,
is being recalled because small amounts of air may have entered
the can, resulting in product oxidation. Consumption of highly
oxidized foods can cause gastrointestinal symptoms such as
nausea, vomiting, and diarrhea. Parents should contact their
healthcare professional if they have any questions or concerns.
May 30,
2008
Audience:
Consumers, healthcare professionals
International Pharmaceuticals, Ltd. and FDA notified consumers
and healthcare professionals that the company is recalling all
supplement products sold under the brand name of Viril-ity Power
(VIP) Tablets. The product is being recalled because one lot was
found to contain a potentially harmful undeclared ingredient,
hydroxyhomosildenafil, an analog of sildenafil. Sildenafil is
the active ingredient in Viagra, an FDA-approved drug used for
erectile dysfunction. The undeclared ingredient may interact
with nitrates found in some prescription drugs (such as
Nitroglycerin) and may lower blood pressure to life-threatening
levels. Consumers with diabetes, high blood pressure, high
cholesterol, or heart disease often take such nitrates.
Consumers who have Viril-ity Power (VIP) Tablets should stop
using it immediately and contact their healthcare professional
if they experience any problems that may be related to taking
this product.
May 29,
2008
Audience:
Nursing mothers, pediatricians, other healthcare professionals
FDA
informed consumers not to use or purchase Mommy's Bliss Nipple
Cream, marketed by MOM Enterprises, Inc., because the product
contains potentially harmful ingredients that may cause
respiratory distress or vomiting and diarrhea in infants. The
product is promoted to nursing mothers to help soothe and heal
dry or cracked nipples. Potentially harmful ingredients in the
product are chlorphenesin and phenoxyethanol. Chlorphenesin
relaxes skeletal muscle and can depress the central nervous
system and cause slow or shallow breathing in infants.
Phenoxyenthanol, a preservative that is primarily used in
cosmetics and medications, can also depress the central nervous
system and may cause vomiting and diarrhea, which can lead to
dehydration in infants. Mothers and caregivers should seek
immediate medical attention if their child shows signs and
symptoms of decreases in appetite, difficulty in awakening,
limpness of extremities or a decrease in an infant's strength of
grip and a change in skin color.
May 27,
2008
Audience:
Consumers, healthcare professionals
FDA
alerted consumers and healthcare professionals not to buy or use
Xiadafil VIP Tablets sold in bottles of 8 tablets (Lot #6K029)
or blister cards of 2 tablets (Lot# 6K029-SEI). The product is
marketed as a dietary supplement and is promoted and sold over
the internet for sexual enhancement and to treat erectile
dysfunction (ED). The product contains a potentially harmful,
undeclared ingredient that may dangerously affect a person's
blood pressure and can cause other life-threatening side
effects. Xiadafil VIP Tablets contain hydroxyhomosildenafil, an
analog of sildenafil, the active ingredient in Viagra, an FDA
approved prescription drug for ED. The undeclared ingredient may
interact with nitrates found in some prescription drugs and can
lower blood pressure to life-threatening levels. Consumers with
diabetes, high blood pressure, high cholesterol, or heart
disease often take nitrates. Consumers who have used the product
should discontinue use immediately and consult their healthcare
professional if they have experienced any adverse events that
they believe may be related to the use of this product.
-
MONSTER OF IRAQ DIED THE WAY YOUR EDITOR
DESCRIBED-OUR READERS WERE THE FIRST ON THE GLOBE TO KNOW THE TRUTH
Some
say that the age of chivalry is past, that the spirit of romance is
dead. The age of chivalry is never past, so long as there is a
wrong left unredressed on earth."
Charles
Kingsley,
Vol.,
II, Ch 28: "A good conscience is a continual Christmas"
Benjamin Franklin
Well,
once again, your certified forensic examiner, proved recreation as
described below was correct. Although your editor has moved
on, it is clear why your Attorney General in 1988 made a law to
limit experts pay. Because on a alleged impossible case, your
AG flew me to Washington DC to solve the issues, which I did in
three to four hours but the pay was $10,000.00 for the case which
was agreed upon prior to my hire, plus a wonderful flight to
Washington DC to meet federal officers, a wonderful lunch and
dinner, and a great flight home. After solving the mystery, they
created a day limit for experts to I believe, sixteen hundred per
day. Perhaps it has been raised by now! When they
stopped paying my price,
(In 1993, one state Justice Department again
paid my price, and flew me back to Washington DC to brainstorm with
federal officers where I lectured for the AG, side by side with the AG
to key government officials, which
resulted in a national alert and elimination of a fifteen state-interstate crime wave
scourge...protecting the remaining states from sustaining massive
citizen victim losses.)
I wrote my book, and until Diana died, we
taught officers on a one on one basis. After that, much of the
book turned into
The
InfoJustice
Journal.
Well after all these years, my forensic abilities
remain in tact. The monster died from concussion or concussive
waves which knocked him out. He did not die from any of the
building falling on him. The concussive blast forces of the bombing
also damaged his lungs from within which caused him to drown in his
own blood. They still claim he was in the house and was bounced
off a wall absent any outside injuries which is nonsense.
He would have a large bruising from the wall against his skin
with particles in his tissues, and damaged clothing which would be
blood soiled. Further if inside the house after
hitting the wall he would have been crushed from the building mass
falling on him. Complete and utter nonsense forensically. There would also be blood splatter
inside the house! But they are wrong! It is
OK on something which is
at this point becoming unimportant and again it is a Bush
administration where being wrong has become standard operating
policy. However, they still remain silent on how this could
occur. Obviously he was issuing out of the house when the
blast forces knocked him out, while tearing his lung tissues
internally and throwing him to the ground awkwardly with great force
breaking his leg. The Blast forces from two 500 pound units is
massive
(Under God, members and "you",
my independent readers now "see", that the truth
was not on any
cable, TV news or print media first. Why, we even beat the most
reliable news network, which put a smile on our board, who are
skeptics
until
proven happy!).
I t is now a fact that you heard the truth first
here at the Journal, "your" source for inside information, and
"where politics end and the truth
begins".
God Bless-"little guy"
-
FDA AND CDC ISSUE
ALERT ON MENACTRA
MENlNGOCOCCAL
VACCINE AND GUILLAIN BARRE SYNDROME 
The Food and Drug Administration (FDA) and Centers for
Disease Control and Prevention (CDC) are alerting consumers and
health care providers to five reports of Guillain Barre Syndrome
(GBS) following administration of Meningococcal Conjugate
Vaccine A, C, Y, and W135 (trade name Menactra), manufactured by
Sanofi Pasteur. It is not known yet whether these cases were
caused by the vaccine or are coincidental. FDA and CDC are
sharing this information with the public now and actively
investigating the situation because of its potentially serious
nature.
Guillain Barre Syndrome (GBS) is a serious neurological
disorder that can occur, often in healthy individuals, either
spontaneously or after certain infections. GBS typically causes
increasing weakness in the legs and arms that can be severe and
require hospitalization.
Meningococcal infection, which Menactra prevents, is a major
cause of bacterial meningitis, affecting approximately 1 in
100,000 people annually. The infection can be life threatening: 10-14 percent of cases are fatal and 11-19 percent of survivors
may have permanent disability.
According to Jesse Goodman, MD, Director of FDA’s Center for
Biologics Evaluation and Research, at the present time there are
no changes in recommendations for vaccination; individuals
should continue to follow their doctors' recommendations. FDA
and CDC are not able to determine if any or all of the cases
were due to vaccination. The current information is very
preliminary and the two agencies are continuing to evaluate the
situation.
Because of the potentially serious nature of this matter, FDA
and CDC are asking any persons with knowledge of any possible
cases of GBS occurring after Menactra to report them to the
Vaccine Adverse Event Reporting System (VAERS) to help the
agencies further evaluate the matter. Individuals can report to
VAERS on the web at www.vaers.hhs.gov <http://www.vaers.hhs.gov>
or by phone at 1-800-822-7967.
The five cases of GBS reported following administration of
Menactra occurred in individuals living in NY, OH, PA, and NJ.
All five patients were 17 or 18 years of age and developed
weakness or abnormal sensations in the arms or legs, two-four
weeks after vaccination. All individuals are reported to be
recovering or to have recovered. More than 2.5 million doses of
Menactra vaccine have been distributed to date. The rate of GBS
based on the number of cases reported following administration
of Menactra is similar to what might have been expected to occur
by coincidence, that is, even without vaccination. However, the
timing of the events is of concern. Also, vaccine adverse events
are not always reported to FDA so there may be additional cases
of which we are unaware at this time.
Prelicensure studies conducted by Sanofi Pasteur of more than
7000 recipients of Menactra showed no GBS cases. CDC conducted a
rapid study using available health care organization databases
and found that no cases of GBS have been reported to date among
110,000 Menactra recipients .
-
CONSUMER
ALERT
Some
say that the age of chivalry is past, that the spirit of romance is dead. The age of chivalry is never past, so long as there is a wrong
left unredressed on earth."
Charles Kingsley,
Vol., II, Ch 28:
"A
good conscience is a continual Christmas." Ben Franklin

Beat the Press News Exclusive:
The following resources have been compiled by
USCDC as a resource for older
adults, their families, friends or caregivers, and those who would
like to contribute to the relief efforts
following the devastation caused by
Hurricane Katrina along the US gulf coast.
The web pages of the following organizations that are principals in
disaster relief provide information on donating cash,
volunteers and products. Each organization
also states how they are aiding relief
efforts.
American Red Cross
http://www.redcross.org/
To donate: Call 1-800-HELP NOW or 1-800-257-7575 (Spanish).
Internet users can make a secure online
contribution by visiting
www.redcross.org.
To volunteer: Individuals interested in volunteering for the
American Red Cross should contact their
local Red Cross chapter.
America's Second Harvest
(non-governmental hunger-relief organization)
http://www.secondharvest.org/
To donate: Internet users can make a secure online contribution by
visiting
www.secondharvest.org.
Companies, manufacturers or retailers wanting to donate a full
truckload of dry storage product, call
1-800-771-2303 and ask for the Food
Sourcing Department Companies wanting to donate transportation of
product, call 1-800-771-2303 and ask for the Logistics Department
The Humane Society of the United States
http://www.hsus.org/
To donate: Internet users can make a secure online contribution by
visiting www.hsus.org.
The American Geriatrics Society
Hurricane Katrina: Informational Resources
http://www.americangeriatrics.org/news/hurricane_katrina.shtml
Comprehensive list of sources of medical information for clinicians
and caregivers, plus disaster and relief
information.
Federal Emergency Management Agency (FEMA)
http://www.fema.gov/
The US federal agency in charge of disaster regularly updates
information on relief efforts, and provides links to a number
of disaster relief organizations.
Hospice Foundation of America Establishes Hospice Patient Locater
Message Board at
www.hospicefoundation.org in Response to Hurricane Katrina
The Salvation Army is currently providing services to storm
survivors and first responders in the Gulf
Coast states as well. You can visit their
website at
www.salvationarmy.com
God Bless the US CDC and the United States of
America.-"InfoJustice"
-
CONSUMER
ALERT
Some
say that the age of chivalry is past, that the spirit of romance is dead. The age of chivalry is never past, so long as there is a wrong
left unredressed on earth."
Charles Kingsley,
Vol., II, Ch 28:
"A
good conscience is a continual Christmas." Ben Franklin

Beat the Press News Exclusive:
You have two weeks left to
register your "cell phone" to block sales calls for five years.
Call...888-382-1222 and follow the instructions. This
public service announcement was brought to you by the
States' Attorney Generals, The Federal Trade Commission and our
Academy Vice President Stormin Norman Udewitz FFAAJTS-InfoJustice
-
MALPRACTICE
GUARANTEE WITH NATUROPATHY

Today we have witnessed the fact that when in
the course of human events, even if a good hearted official in a land
is perceived as having appointed cronies, and perceived to have made war
based on good intentions but unsubstantiated claims, then subsequently because mass media has
homogenized human personality and indeed
that trait to make unsubstantiated unscientific claims, copy-cat individuals with
personality across
that land absent
that official's ethics, IQ, and any care for the truth will and
have infiltrated many many
businesses and the private sectors in that land, and will have paid off
weak willed
researchers at Universities bringing that lands educational and
medical systems to the status of the old communist Russia; just
corrupt and dragging the rest of society down. It is OK to
lie... This is all very very sad.
In the US a symptom of this scourge is the
evolving Supplement Naturoquackery movement. Professionally, US Government statistics reveal that
every Naturopath will eventually be involved in the quack caused
injury claim by a US citizen!
"Homeopaths and naturopaths had an average of 1.0
malpractice reports made against each of them in the US 1990-2003
(2003 Annual Report, National Practitioner Data Bank, US DHHS)".
This editor reported the fact that it was
taught that it is OK to take revenge on patients and use medicine as
a weapon. This was taught in a clinic setting during official
student training. When the whistleblower brought this to the
attention of all of the gate US Naturopathic Schools, they all admitted
this and other reported behaviors were normal and customary and to criticize
or critique was
un-naturopathic. The President of one Naturopathic College
wrote to the whistleblower about reporting criminal activity within
Naturopathy, "It is not who is right or wrong in life it is how you
play the game." You just cannot make this stuff up! This is a
national crisis in the making.-InfoJustice
-
FDA's New Influenza Vaccine for
Upcoming Flu Season
The Food and Drug Administration (FDA) today approved Fluarix, an
influenza vaccine for adults that contains inactivated virus.
Fluarix is approved to immunize adults 18 years of age and older
against influenza virus types A and B contained in the vaccine.
Influenza is also commonly called the flu.
"FDA"s approval of Fluarix is a big step toward providing an
adequate supply of flu vaccine for the American public," said Mike
Leavitt, Secretary of Health and Human Services (HHS). "Having more
manufacturers of influenza vaccine licensed in the U.S., and having
more vaccine dosages, is critical to public health and I applaud FDA
for taking such quick action to obtain and evaluate the data needed
to license Fluarix in time for this year"s influenza season."
The approval of Fluarix breaks new ground in that it is the first
vaccine approved using FDA"s accelerated approval process.
Accelerated approval allows products that treat serious or
life-threatening illnesses to be approved based on successfully
achieving an endpoint that is reasonably likely to predict ultimate
clinical benefit, usually one that can be studied more rapidly than
showing protection against disease. In this case, the manufacturer
demonstrated that after vaccination with Fluarix adults made levels
of protective antibodies in the blood that FDA believes are likely
to be effective in preventing flu. GlaxoSmithKline, the manufacturer
of Fluarix, will do further clinical studies as part of the
accelerated approval process to verify the clinical benefit of the
vaccine.
"Previous shortages highlighted the need for additional influenza
vaccine manufacturers for the U.S. market," said FDA Commissioner
Lester Crawford. "Accelerated approval has allowed us to evaluate
and approve Fluarix in record time so that we can make available
additional safe and effective flu vaccines. I commend our Center for
Biologics for taking extraordinary steps to help us be better
prepared for both the upcoming and future flu seasons."
This success required close cooperation among the FDA, the
National Institutes of Health, and the product manufacturer," said
Dr. Jesse Goodman, Director of FDA"s Center for Biologics Evaluation
and Research. "The dedicated staff of this Center is doing
everything possible to prepare for the upcoming flu season."
FDA based the accelerated approval of Fluarix on thorough
evaluation of safety and effectiveness data from four clinical
studies involving approximately 1,200 adults. Other data from
post-marketing reports in other countries where Fluarix is already
approved were also reviewed as part of FDA"s safety assessment.
In the United States it is estimated that more than 200,000
people are hospitalized from flu complications, and about 36,000
people die from flu each year. Although no vaccine is 100% effective
against preventing disease, vaccination is the best protection
against influenza and can prevent many illnesses and deaths.
Fluarix is manufactured in Dresden, Germany by Sächsisches
Serumwerk (SSW), a subsidiary of GlaxoSmithKline Biologicals, of
Rixensart, Belgium. It will be distributed by GSK in Research
Triangle Park, NC.
-
FDA STRENGTHENS RISK MANAGEMENT PROGRAM;
ISOTRETINOIN (ACCUTANE) DURING PREGNANCY
The U.S. Food and Drug Administration (FDA) is announcing
approval of a strengthened distribution program for isotretinoin,
called iPLEDGE, aimed at preventing use of the drug during
pregnancy. Women who are pregnant or who might become pregnant
should not take the drug. Isotretinoin (Accutane and its generics)
is a highly effective drug for severe recalcitrant nodular acne, but
it carries a significant risk of birth defects if taken during
pregnancy.
The manufacturers are implementing a program that requires
registration in iPLEDGE by doctors and patients who agree to accept
specific responsibilities before receiving authorization to
prescribe or use the drug. These measures are designed to guard
against pregnancies while using the drug. Wholesalers and pharmacies
must also comply with the manufacturers' program requirements in
order to distribute and dispense the product. FDA is approving this
program under its regulations, known as Subpart H, that require
restrictions on the distribution of a drug to assure safe use.
"This stronger program is a major step in protecting against
inadvertent pregnancy exposure by tightly linking negative pregnancy
testing with dispensing of isotretinoin." said Dr. Steven Galson,
Director, FDA's Center for Evaluation and Research. "iPLEDGE, using
a computer-based and telephone system, will provide health care
professionals with the real time information necessary to
effectively manage the risks of isotretinoin."
In February 2004, at a joint meeting, FDA's Drug Safety and Risk
Management Advisory Committee and Dermatologic and Ophthalmic Drugs
Advisory Committee reviewed the existing isotretinoin risk
management programs in effect at that time. Based upon their review,
the joint committee called for major improvements in the restricted
distribution program, including mandatory registration to ensure
that patients who could become pregnant have negative pregnancy
testing and birth control counseling before receiving the drug.
To inform health care providers about iPLEDGE, FDA has issued a
Public Health Advisory and revised the Patient and Health Care
Provider Information Sheets that detail the tightened restrictions
and increased responsibilities under iPLEDGE for prescribing,
dispensing, distributing, and obtaining isotretinoin.
To obtain the drug, in addition to registering with iPLEDGE,
patients must comply with a number of key requirements that include
completing an informed consent form, obtaining counseling about the
risks and requirements for safe use of the drug, and, for women of
childbearing age, complying with required pregnancy testing.
A reporting and collection system for serious adverse events
associated with the use of istotretinoin has also been implemented.
All pregnancy exposures to isotretinoin must be reported immediately
to the FDA via the MedWatch 1800-FDA-1088 and to the iPLEDGE
pregnancy registry at 1-866-495-0654 or on the iPLEDGE website.
Doctors, patients, and pharmacies can obtain program information
and register with iPLEDGE via the internet, beginning August 22,
2005, at www.ipledgeprogram.com or telephone 1-866-495-0654.
In addition to approving the iPLEDGE program, FDA has approved
changes to the existing warnings, patient information and informed
consent document so that patients and prescribers can better
identify and manage the risks of psychiatric symptoms and depression
before and after prescribing isotretinoin.
Under the program, after October 31, 2005, wholesalers and
pharmacies will have to register with iPLEDGE to obtain isotretinoin
from a manufacturer. Starting December 31, 2005, all patients and
prescribers (doctors) must register and comply with requirements for
office visits, counseling, birth control and other responsibilities.
The manufacturers participating in the iPLEDGE program include:
Hoffman-LaRoche manufacturer of Accutane; Genpharm manufacturer
of Amnesteem which is distributed by Mylan/Bertek; Ranbaxy
Pharmaceuticals manufacturer of Sotret; and Barr Laboratories
manufacturer of Claravis.
BRILLIANT US DISTRICT
JUDGE ISSUES INJUNCTION, USFDA INVESTIGATED THEN
BLOCKS SALE OF ILLEGAL
DRUGS
The U.S. Food and Drug Administration (FDA) today announced a
permanent injunction shutting down operations at Pharmakon Labs of
Florida. The company manufactured and distributed cough and cold
liquids, tablets and caplets.
Following inspections by FDA and a trial in U.S. District Court,
Judge Richard A. Lazzara found that drug products sold by Pharmakon
Labs, Inc., its president Abelardo L. Acebo, and its
secretary/treasurer Edward R. Jackson (the defendants) did not meet
current good manufacturing practice (cGMP) standards and other legal
requirements.
Judge Lazzara stated that he was "simply unwilling as a court of
equity to place the health, safety, and welfare of the general
public at risk in order to accommodate the economic well-being of
Defendants." Thus, the defendants were ordered to stop manufacturing
and distributing drugs until they become compliant with CGMP
standards to the satisfaction of FDA and obtain marketing approvals.
"This action by Judge Lazzara sends a strong signal that FDA will
take action against drugs that fail to meet quality standards," said
FDA Commissioner Dr. Lester M. Crawford. "As the nation's top
enforcer of manufacturing standards, the FDA will continue to ensure
that drugs being sold in this country meet those crucial
requirements."
The defendants have a long history of continued violations of the
Federal Food, Drug, and Cosmetic Act. The government's initial
complaint alleged numerous manufacturing violations documented in
four inspections dating back to 2001. FDA later added charges
related to Pharmakon's manufacture and distribution of unapproved
new drugs, as part of the agency's longstanding policy to seek
relief for all legal violations by a firm at the same time.
The government's request for a permanent injunction was based on
the defendants' demonstrated unwillingness to comply with the law.

The Board of Directors and the members of the
American Academy for Justice Through Science wish our deepest heart felt
condolences to fellow member James Drury DO FAAJTS, and to his family
and friends for the loss of his father; a retired veteran of the Korean
War serving on the USS Coral Sea. He then went on to have an
illustrious life of service to the people of New York as one of New
York's finest, New York Police Officer. In fact neighbors on
Officer James
Drury's beat slept safely in their beds
as he could be heard saying "Nothing to Report" which meant all
were safe.
A note to your Sir in Heaven from your son, our brother and fellow of
the Academy, "Rest
In Peace, Dad...Nothing to Report."-J
Drury DO AAJTS ANTI-LONGEVITY MOVEMENT
EXCLUSIVE
Some
say that the age of chivalry is past, that the spirit of romance is
dead. The age of chivalry is never past, so long as there is a wrong
left unredressed on earth."
Charles
Kingsley,
Vol., II,
Ch 28: "A
good conscience is a continual Christmas." Ben
Franklin

InfoJustice research has found the actual denial from
USFDA on a Growth Hormone Product, yet it has infiltrated consumers
promoted by unscrupulous individuals whose intent is anarchy and
criminal profit.
The links for Anhui Metals and Minerals Anhui, CN SAN-DO
AEK-6664026-5/1/1 64RCY21 SOMATROPIN GROWTH HORMONES 02-MAY-2005 follow:
NOT LISTED
DIRECTIONS
DRUG GMPS
DRUG NAME
UNAPPROVED
America, The American Academy For Justice Through
Science is proud to Beat the Press, and continue to protect the consumer
public, through education and information. God Bless-InfoJustice
FDA ISSUES PUBLIC
HEALTH ADVISORY FOR MIFEPRISTONE
The Food and Drug Administration (FDA) is investigating
recently reported serious adverse events associated with
mifepristone (trade name Mifeprex, also known as RU-486). As a
result, the FDA is issuing a public health advisory today
highlighting the risk of sepsis or blood infection when
undergoing medical abortion using Mifeprex and misoprostol in a
manner that is not consistent with the approved labeling. There
are now four cases of deaths from infection from September 2003
to June 2005 following medical abortion with these drugs.
"The FDA is committed to sharing emerging drug information
with the public and we believe it is important to share with
healthcare providers and patients the latest serious reports of
infection associated with this drug that we have received," said
Dr. Steven Galson, Acting Director of FDA's Center for Drug
Evaluation and Research.
The bacteria thought to have caused the fatal infection have
been identified in two of the cases and the other two cases are
under investigation by FDA along with the Centers for Disease
Control and Prevention, State and local health departments, and
the manufacturer of Mifeprex. Doctors are urged to have a higher
level of suspicion for sepsis in their patients taking Mifeprex.
Previously, the FDA has received reports of serious bacterial
infection, bleeding, ectopic pregnancies that have ruptured, and
death. Those reports led to the revision of the black box
labeling. Mifeprex was approved by the FDA in 2000.
-
ANTI-LONGEVITY MOVEMENT
EXCLUSIVE
Some
say that the age of chivalry is past, that the spirit of romance is
dead. The age of chivalry is never past, so long as there is a wrong
left unredressed on earth."
Charles
Kingsley,
Vol., II,
Ch 28: "A
good conscience is a continual Christmas." Ben
Franklin
There is sick movement capitalizing on the
gullibility, medical folly, and good nature of the American Citizen.
This "Crime wave", has infiltrated the US medical industry.
Readers
of this press are the first to know in the general public, as no press
releases have been noted, that fraudulent and poor quality
pharmaceuticals have been identified as coming in from China.
Sources advise that USFDA is presently undergoing a brilliant effort to
curb, seize, and deter future fraud in the natural health bio-supplement
and supplement industry.
Seizures have begun according to today's Beat the Press' source.
What is disgusting to me, is that organized crime,
profits off the sick. And now they have infiltrated the medicinal
chain for pediatric disease and the natural
health longevity industries. Relative to our children, if we don't
protect them, our entire future as a nation is in jeopardy.
Clearly, if we don't act fast, the best
prophylactic and prevention of the crime, the witness, will
die or become deformed, absent the chance to point out that a Human Growth Hormone
product was Promoted as
FDA approved. Yet what was provided was a product the FDA never
approved and studies now indicate, could cause Addison's disease in
adults and fail the anticipated needs of the pediatric endocrinologists
(MD). -"Beat
the Press Exclusive News Alert"-InfoJustice
-
GROOMING; GODS WAYS ARE
NOT OUR WAYS
I believe that life's wavering trails, teaches us
what's on the surface is not always through to the core. And that wise
folks remember the events of the journey, report to our fellow man, and
improve the journey for all that follow. I see a very interesting
molding occurring right now. Of course the horrors of all of the
hurricanes which hit Florida and continue to trouble the Sunshine state
are of paramount concern to the nation, but has anyone noticed how all
of the troubles are being handled quite well by Governor Jeb Bush.
It seems to me, that perhaps the honorable governor is being honed by
time and history, to become a viable candidate for President of the
United States. Lets keep our eye on that story for the molding of
a person through tough times, often can produce someone all of us need,
for no one is immune to the luck of fate. For example, the con
stories of health care hucksters who really are trying to get your money
in lieu of properly educated and trained medical advice especially when
your back is turned, when your guard is down because of illness, when
your are too ill to make healthy contemplations about drugs, herbs,
lotions, potions, decoctions, tinctures, sensory stimulations reported
to cure all of the ills of mankind, wild and wacky electrical gizmos all
presented during the worst period of your life, when your are ill.
We need the experienced folks to rise to the top
during our times of need. I see a molding of a man occurring in
Florida and dare say that if ones' Job performance is a criteria, that
the honorable Jeb Bush must be considered a viable candidate for
President of the United States of America. The American
Academy For Justice Through
Science
humbly submits our nations Man of the summer season, Florida's own,
honorable Governor John Ellis "Good Job Jeb" Bush.
Congratulations.-"InfoJustice"
-
ACADEMY NEWS-NEW LIFE
FELLOW
Under
and by virtue of the full authority,
provisions and privileges vested herein,
the American Academy For Justice Through Science
proclaim that in recognition of
his valuable contributions in Ethics,
Outstanding Medicine, and service to the public trust, hitherto Dr.
Charles Duvall DC FAAJTS Ohio-#2010, Anti-Fraud Expert, life
fellowship, full rights, privileges and honors status in the
American Academy For Justice Through Science' as a 2005 Fellow
of the Board.
Congratulations - Press Release
-
FDA Issues Nationwide Alert for "Liqiang 4"
Due to Potential Health Risk 
The U.S. Food and Drug Administration (FDA) is warning consumers not
to take Liqiang 4 Dietary Supplement Capsules because they contain glyburide
– a drug that could have serious, life-threatening consequences in some
people.
Glyburide is a drug used to lower blood sugar, and is safe and
effective when used as labeled in FDA-approved medications. People who
have low blood sugar or those with diabetes can receive dangerously high
amounts of glyburide by consuming Liqiang 4. Consumers should
immediately stop using these products and seek medical attention,
especially if they are currently being treated with diabetes drugs or if
they have symptoms of fatigue, excessive hunger, profuse sweating, or
numbness of the extremities. Consumers who have this product should
dispose of it immediately.
The product is sold as part of a shrink-wrapped two bottle set. One
of the 90 capsule bottles is labeled Liqiang 4 Dietary Supplement
Capsules, the other bottle is promoted as a “bonus pack” of Liqiang 1.
At this time FDA is evaluating Liquang 1 and other versions of this line
of products to determine their composition and safety. The product is
manufactured by Liqiang Research Institute, China, and marketed
throughout the United States in herbal stores and through mail order by
Bugle International of Northridge CA.
The FDA learned of the potential problem through an anonymous
consumer complaint and followed up with testing that revealed the
presence of glyburide in this product.
The product has also been termed "Liqiang Xiao Ke Ling" (Liqiang
Thirst Quenching Efficacious) in ads in Chinese language publications
which also promote it as useful for the control of diabetes and being
derived from only natural ingredients.
FDA encourages consumers, health care providers, and caregivers to
report any adverse events related to this product to MedWatch, the FDA's
voluntary reporting program at 1-800-FDA-1088; by FAX at 1-800-FDA-0178;
by mail to MedWatch, Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD, 20857-9787; or online at
www.fda.gov/medwatch/report.htm.
-
FDA Issues Information for Consumers about
Claims for Green Tea and Certain Cancers
Under the Food and Drug Administration's (FDA) "Consumer Health
for Better Nutrition Initiative," the Agency is announcing the
results of a review of qualified health claims that green tea may
reduce the risk of certain types of cancer. Based on a systematic
evaluation of the available scientific data, the FDA intends to
consider exercising its enforcement discretion for the following
qualified health claims for breast and prostate cancer:
"Two studies do not show that drinking green tea reduces the risk
of breast cancer in women, but one weaker, more limited study
suggests that drinking green tea may reduce this risk. Based on
these studies, FDA concludes that it is highly unlikely that green
tea reduces the risk of breast cancer"; and
"One weak and limited study does not show that drinking green tea
reduces the risk of prostate cancer, but another weak and limited
study suggests that drinking green tea may reduce this risk. Based
on these studies, FDA concludes that it is highly unlikely that
green tea reduces the risk of prostate cancer."
The FDA also concluded that existing evidence does not support
qualified health claims for green tea consumption and a reduced risk
of any other type of cancer.
Guidance on qualified health claims for conventional foods and
dietary supplements was issued by the FDA in July 2003. FDA will
continue to evaluate new information that becomes available to
determine whether changes in these claims, or in the decision, are
necessary.
-
ACADEMY NEWS-NEW LIFE
FELLOW
Under
and by virtue of the full authority,
provisions and privileges vested herein,
the American Academy For Justice Through Science
proclaim that in recognition of
her valuable contributions in Ethics,
Outstanding Medicine, and service to the public trust, hitherto Dr.
Marie King PhD FAAJTS CA-#2008, Forensic Clinical Psychologist, life fellowship, full rights, privileges and honors status in the
American Academy For Justice Through Science' as a 2005 Fellow of the
Board.
Congratulations - Press Release
-
LETTER TO THE EDITOR
Some
say that the age of chivalry is past, that the spirit of romance is
dead. The age of chivalry is never past, so long as there is a wrong
left unredressed on earth."
Charles
Kingsley,
Vol., II,
Ch 28: "A
good conscience is a continual Christmas." Ben
Franklin
Dear Dr. Neff,
I've been in contact with the people in Iowa that help victims.
But the problem with my pains
and memory loss was related to
my thyroids
all this time! I
feel deep sadness from what's happened;
eight years wasted,
sometimes it feels weird seeing my
nine grandchildren and not remembering 5 of their births!
You see I had a great
memory and ears like tape recorders. Now part of the gifts that I was born with have
been erased, but the most sadness came...(Editor's
Note: The rest of Paula's statements were simply too personal in
nature relative to her loss of health.).
Thank you for your emails
and good advice.
It's good to know
someone still has a heart!
Paula Nelson-05-21-2005
-"InfoJustice"
-
ACADEMY NEWS-NEW MEMBERS
Under
and by virtue of the full authority,
provisions and privileges vested herein,
the American Academy For Justice Through Science
proclaim that in recognition of
valuable contributions in Ethics,
Outstanding Medicine, and service to the public trust and the Academy,
hitherto Dr. Alan Dinehart DC MD FAAJTS CA & SC-#2009, full fellowship, rights, privileges and honors status in the
American Academy For Justice Through Science' as a 2005 Fellow of the
Board.
Congratulations - Press Release
-
FDA APPROVES NEW COMBINATION VACCINE FOR
ADOLESCENT AND ADULT WHOOPING COUGH

The Food and Drug Administration (FDA) today approved a new vaccine
for a single booster immunization against pertussis (whooping
cough), in combination with tetanus and diphtheria, for adolescents
and adults 11-64 years of age. The vaccine will be marketed as
Adacel by Aventis Pasteur Limited located in Toronto, Canada. Adacel
is the first vaccine approved as a pertussis booster for adults.
Vaccines for prevention of tetanus and diphtheria (Td vaccine) in
adolescents and adults have been available for many years.
Adacel is a Tetanus Toxoid (T), Reduced Diphtheria Toxoid (d) and
Acellular Pertussis Vaccine (ap), Adsorbed. Adacel contains the same
components as Daptacel, a DTaP vaccine indicated for infants and
children manufactured by Aventis Pasteur Limited, but the diphtheria
toxoid and one of the pertussis components are in reduced quantities.
Recently, FDA approved a similar vaccine called Boostrix,
manufactured by GlaxoSmithKline, for use in adolescents 10-18 years of
age.
Pertussis is a highly communicable and potentially serious illness in
adolescents and adults, and can cause prolonged cough and missed days at
school and work. In young infants, pertussis is more frequently severe
and can be fatal, particularly in those too young to be fully
vaccinated. Since 1980, the rates of reported pertussis cases have been
increasing in adolescents and adults, as well as in young infants.
Adolescents and adults have been implicated as the source of pertussis
infection for susceptible young infants, and other family members.
The ability of Adacel to protect against pertussis was assessed by
comparing the antibody responses of adolescents and adults who received
it with the antibody responses of infants who had received Daptacel in a
clinical trial. The antibody responses of the adolescents and adults who
received a single dose of Adacel were at least as good as those observed
in the infants following three doses of Daptacel. For diphtheria and
tetanus, the antibody responses following Adacel were comparable to
those following immunization with a U.S. licensed Td vaccine.
In clinical trials, the safety of Adacel was compared to a U.S.
licensed Td vaccine. Among adolescent recipients of Adacel, injection
site pain and low grade fever were observed more frequently than among
those who received Td vaccine. Rates of adverse reactions were similar
in adults receiving Adacel vaccine or receiving Td vaccine.
-
FTC PUTS THE SQUEEZE ON TROPICANA'S ORANGE JUICE
CLAIMS
The Federal Trade Commission has settled a
complaint against Tropicana Products, Inc., in which it alleged the
company misled consumers with claims that drinking two to three
glasses a day of its “Healthy Heart” orange juice would produce
dramatic effects on blood pressure, cholesterol, and homocysteine
levels, thereby reducing the risk of heart disease and stroke. Under
the terms of the consent agreement settling the charges, Tropicana
is prohibited from making similar health-related claims in the
future unless they can be substantiated by reliable scientific
evidence.
According to the Commission, Tropicana ran the
“Healthy Heart” ads between 2002 and early 2004, on television and in
publications such as Newsweek magazine. The ads claimed that drinking
two to three cups of Tropicana orange juice each day would lower
systolic blood pressure by 10 points, raise HDL cholesterol by 21
percent and improve the HDL to LDL cholesterol ratio by 16 percent,
increase blood folate levels by 45 percent and lower blood homocysteine
levels by 11 percent. The complaint charges that the benefits were not
substantiated and claims of clinical support for them were false.
“Orange juice contains many nutrients
important to a healthy diet, and advertising can be an important source
of information about the health benefits of foods,” said Lydia Parnes,
Director of the Bureau of Consumer Protection. “But it is essential that
such advertising be truthful. In this case Tropicana’s claims went well
beyond its scientific support.”
According to the Commission, Tropicana ran the
“Healthy Heart” ad as a two-page spread in Newsweek magazine in February
2004. In 2002, Tropicana ran a more extensive national advertising
campaign, including several television commercials and a full-page print
ad in the New York Times, as cited in the Commission’s complaint. The
2002 ad campaign made a claim virtually identical to the 10-point blood
pressure reduction claim that appeared in the 2004 advertising. The
Commission staff had specifically expressed its concerns about the blood
pressure claim made in the earlier campaign in a public closing letter
in July 2002, but did not seek formal agency action at that time. As the
letter noted, although foods that are rich in potassium and low in
sodium such as orange juice have been recognized by public health
authorities, including the Food and Drug Administration (FDA), to help
reduce the risk of hypertension and stroke, the 10-point blood pressure
reduction claim did not appear to be substantiated.
The Commission’s complaint charges Tropicana with
making unsubstantiated claims that: 1) drinking three cups of Tropicana
orange juice a day for four weeks will raise HDL cholesterol by 21
percent and improve the ratio of HDL to LDL cholesterol by 16 percent;
2) drinking 20 ounces of Tropicana orange juice a day will increase
blood levels of folate by almost 45 percent and decrease homocysteine
levels by 11 percent; and 3) drinking two cups of Tropicana orange juice
a day for six or eight weeks will lower systolic blood pressure an
average of 10 points. The complaint also charges that Tropicana’s claims
that clinical studies demonstrated these benefits were false.
The consent order prohibits Tropicana from making
the challenged claims or any similar claims about the effects of orange
juice or other foods on blood pressure, cholesterol levels, folate
levels, and homocysteine levels or other biological markers or
health-related endpoints unless the company substantiates the claim with
competent and reliable scientific evidence. The order also prohibits
claims by Tropicana that any food will have an effect on the risk of
heart disease, stroke, or cancer unless substantiated by competent and
reliable scientific evidence. The order also prohibits any
misrepresentations relating to tests or studies. Tropicana is permitted
under the settlement to make certain claims that comply with specific
FDA regulations for food labeling. Finally, the order contains various
record keeping requirements to assist the FTC in monitoring compliance.
-
HAPPY MEMORIAL DAY; PLEASE
BE CAREFUL AND WATCH
YOUR KIDS.
Please have a safe and happy holiday. And
may our troop abroad come home safe and soon. Yet, "Memorial Day" is one of those special
holiday's statistically, which has very high incidents of injuries.
Children exited to get into the water for the first time this year, (oceans, lakes, rivers, and
swimming pools) sustain serious neck and spine injuries. These
life threatening injuries can be avoided by becoming aware of the
"holiday psychology in play", advise your children accordingly, and try
to keep a special eye out for accidents. Primarily the water
injuries are sustained by diving and hitting the skull, although other
out door water sports must be supervised such as waterskiing,
surfboarding and the like. If you or your children compete in a
new spring event which requires exercise, warm up, stay out of prolonged
sun exposure, and bring electrolytes or even a combination of the simple
salts such as table salt, and 'kosher for their sodium and potassium
respectively.
If you can prepare "Gator-aid" like drinks, these will be
sufficient.
Consult your family physician for in-depth advise.
With the warmest of hopes, the members of the
American Academy For Justice Through Science wish all Americans, a
happy, healthy, thought
provoking and safe Memorial Day weekend.-"InfoJustice"

-
LETTERS TO THE EDITOR
Dear Dr. Neff,
I was injured and treated by
Doctor who put me on SSI and treated me
as mental patient. My dead line for
finding an attorney is Aug. of this year. Have a
doctor now treating me for posttraumatic...
and can truly say the meds first doctor had me on were not only wrong
but going off the charts. Also
I suffer lots of memory loss.
Is there truly still justice
for the poor or only for those who can afford it?
Dear Paula, I am also from the great
heartlands, and my social mores and sound ethics have proved that today
is one of the most anti-justice, anti-science and anti-truth periods of
the last 50 years. Quackery, fraud, hucksterism and folks who just
don't give a hoot about the truth are very prevalent today. There
are many folks who wish to rip off the insurance industry or steal
money from you when you are ill, disabled or especially on fixed incomes
or poor. There are folks out there only after your money
offering you incorrect medicinal substitutes which you discovered and
described above in laymen's terms, " not only wrong but going off
the charts" .
Be careful with your own health. I will document your case further
should you continue.
Finally, seek out a quality specialist to
assist your new doctor and attorney
by August. Do this by simply calling your states Medical Board and
State Bar and get a referral for an MD and an attorney who specializes
in working within the medicine arena. Take an action step and act
now. If you need more assistance I will do what I can.-"InfoJustice"
-
HUMONGOUS ABLE LABS
RECALL FOR DRUGS WITH TAINTED
ACETAMINOPHEN
Able Laboratories of Cranbury, NJ, is conducting a nationwide
recall of all of its manufactured drugs (mostly generic prescription
drugs, including drugs containing acetaminophen) because of serious
concerns that they were not produced according to quality assurance
standards. Able Laboratories has ceased all current production.
"The FDA continues to evaluate the situation at Able Laboratories to
determine the safety and quality of their products and will update the
public on our findings as necessary," said Margaret O'K. Glavin,
Associate Commissioner for Regulatory Affairs. "In the meantime, the
Agency recommends that people who have been taking drugs produced by
this firm speak with their health care provider or pharmacist to obtain
a replacement drug product. The drug recall
involves well over 150 different drug products which also contain
Acetaminophen. The drugs include such favorites as tablet
Hydrocodone, Codeine, Lithium, Naproxen Sodium, Nitroglycerin
Sublingual, Promethazine, Theophyllyine, and much much more as well as a
list of inhaled and liquid medicines.-"InfoJustice"
- COUNTERFEIT LIPITOR,
VIAGRA AND EVISTA
The Food and Drug Administration has approved Requip (ropinirole) to
treat moderate to severe Restless Legs Syndrome (RLS). The drug was
first approved for Parkinson’s disease in 1997.
Restless Legs Syndrome is a condition that affects about ten percent
of the population. The disorder is characterized by an urge to move the
legs, usually accompanied by or caused by uncomfortable leg sensations.
For most people with the condition, symptoms begin or worsen during
periods of rest or inactivity and are partially or totally relieved by
movement. Symptoms typically worsen or occur only in the evening or at
night, and can disturb sleep.
Requip was found to be effective for RLS in three randomized,
d |